Key Takeaways
- • Epitome Therapeutics, a Vienna-based biotech startup founded in 2025 as a spin-off from EMBL Rome, has secured €4 million in total funding following an oversubscribed pre-seed round as of June 30, 2026.
- • The company is developing CADENCE, a next-generation epigenome editing platform designed to enable precise, durable, and context-dependent control of gene expression without altering underlying DNA sequences.
- • Epitome's funding will support advancement of its therapeutic programs and expansion of its team to commercialize its epigenome editing technology platform.
- • The company targets diseases driven by dysregulated gene activity, positioning epigenome editing as a novel therapeutic modality distinct from traditional gene editing approaches.
Summary
Epitome Therapeutics, an early-stage Austrian biotechnology company headquartered in Vienna, has announced the completion of a €4 million pre-seed funding round as of June 30, 2026. The round was oversubscribed, reflecting investor confidence in the company's technology platform and scientific foundation. Founded in 2025 as a spin-off from EMBL Rome, Epitome represents a translation of European scientific research into clinical therapeutics.
The company is developing CADENCE, a proprietary epigenome editing platform that represents a distinct approach within the gene regulation space. Unlike traditional gene editing methods that alter DNA sequences, CADENCE enables precise and durable control of gene expression through epigenetic modifications, with the ability to maintain context-dependent regulation. This mechanistic approach positions Epitome to address therapeutic opportunities in diseases characterized by dysregulated gene activity, a substantial market segment within precision medicine.
The €4 million in funding will be deployed to advance Epitome's pipeline programs and expand its operational team. As an early-stage biotech entity still in the post-launch phase, capital allocation toward program advancement and talent acquisition represents standard venture-backed biotechnology development priorities. The company's focus on epigenome editing technology, which remains an emerging modality with significant intellectual property potential, aligns with broader institutional investor interest in next-generation therapeutic platforms within the European biotech ecosystem.
The company is developing CADENCE, a proprietary epigenome editing platform that represents a distinct approach within the gene regulation space. Unlike traditional gene editing methods that alter DNA sequences, CADENCE enables precise and durable control of gene expression through epigenetic modifications, with the ability to maintain context-dependent regulation. This mechanistic approach positions Epitome to address therapeutic opportunities in diseases characterized by dysregulated gene activity, a substantial market segment within precision medicine.
The €4 million in funding will be deployed to advance Epitome's pipeline programs and expand its operational team. As an early-stage biotech entity still in the post-launch phase, capital allocation toward program advancement and talent acquisition represents standard venture-backed biotechnology development priorities. The company's focus on epigenome editing technology, which remains an emerging modality with significant intellectual property potential, aligns with broader institutional investor interest in next-generation therapeutic platforms within the European biotech ecosystem.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.